Biogen Idec (BIIB) - FREE Research Report Scangos George A who is Chief Executive Officer at Biogen Idec sold 2,239 shares at $245.57 on Nov. 5, 2013. Following this transaction, the Chief Executive Officer owned 39,044 shares meaning that the stake was reduced by 5.42% with the 2,239 share transaction. Schenk Lynn who is Director at Biogen Idec sold 1,000 shares at $245.00 on Nov. 5, 2013. Following this transaction, the Director owned 5,100 shares meaning that the stake was reduced by 16.39% with the 1,000 share transaction. The shares most recently traded at $242.00, down $3.00, or 1.24% since the insider transaction. Historical insider transactions for Biogen Idec go as follows:
12-Week # shares sold: 14,687
24-Week # shares sold: 32,993
The average volume for Biogen Idec has been 1.1 million shares per day over the past 30 days. Biogen Idec has a market cap of $56.7 billion and is part of the health care sector and drugs industry. Shares are up 64.02% year to date as of the close of trading on Tuesday. Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. The company has a P/E ratio of 33.7. Currently there are 12 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 6 rate it a hold. Exclusive Offer: Get the latest Stock Analysis on BIIB - FREETheStreet Quant Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Biogen Idec Ratings Report from TheStreet Quant Ratings now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.